PFIZER INC - FORM 8-K - EX-99 - EXHIBIT 99

Attached files

file	filename
8-K - 8-K - PFIZER INC	pfe-12312013x8k.htm

Exhibit 99

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2013 RESULTS;

PROVIDES 2014 FINANCIAL GUIDANCE


▪	Fourth-Quarter 2013 Reported Revenues⁽¹⁾ of $13.6 Billion; Full-Year 2013 Reported Revenues⁽¹⁾ of $51.6 Billion


▪	Fourth-Quarter 2013 Adjusted Diluted EPS⁽²⁾ of $0.56, Reported Diluted EPS⁽¹⁾ of $0.39; Full-Year 2013 Adjusted Diluted EPS⁽²⁾ of $2.22, Reported Diluted EPS⁽¹⁾ of $3.19


▪	Repurchased $4.6 Billion and $16.3 Billion of Common Stock in Fourth-Quarter and Full-Year 2013, Respectively; Returned Approximately $23 Billion to Shareholders Through Share Repurchases and Dividends in 2013


▪	Provides 2014 Financial Guidance

NEW YORK, N.Y., Tuesday, January 28, 2014 – Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2013. As a result of the full disposition of Zoetis⁽³⁾ on June24, 2013, the financial results of the Animal Health business are reported as a discontinued operation in the consolidated statements of income for full-year 2013, and fourth-quarter and full-year 2012. Results and guidance are summarized below.

OVERALL RESULTS


($ in millions, except per share amounts)	Fourth-Quarter			Full-Year
	2013	2012	Change	2013	2012	Change
Reported Revenues⁽¹⁾	$ 13,558	$ 13,891	(2%)	$ 51,584	$ 54,657	(6%)
Adjusted Income⁽²⁾	3,686	3,391	9%	15,288	15,749	(3%)
Adjusted Diluted EPS⁽²⁾	0.56	0.46	22%	2.22	2.10	6%
Reported Net Income⁽¹⁾	2,568	6,315	(59%)	22,003	14,570	51%
Reported Diluted EPS⁽¹⁾	0.39	0.85	(54%)	3.19	1.94	64%

BUSINESS UNIT⁽⁴⁾ REVENUES


($ in millions) Favorable/(Unfavorable)	Fourth-Quarter				Full-Year
	2013	2012	% Change		2013	2012	% Change
	2013	2012	Total	Oper.	2013	2012	Total	Oper.
Primary Care	$ 3,442	$ 3,833	(10%)	(8%)	$ 13,272	$ 15,558	(15%)	(13%)
Specialty Care	3,397	3,668	(7%)	(5%)	13,288	14,151	(6%)	(4%)
Emerging Markets	2,749	2,652	4%	9%	10,215	9,960	3%	6%
Established Products	2,424	2,370	2%	6%	9,457	10,235	(8%)	(5%)
Consumer Healthcare	943	936	1%	2%	3,342	3,212	4%	5%
Oncology	468	370	26%	29%	1,646	1,310	26%	29%
Other⁽⁵⁾	135	62	*	*	364	231	58%	57%
Total	$ 13,558	$ 13,891	(2%)	1%	$ 51,584	$ 54,657	(6%)	(4%)

* Calculation not meaningful.

- 1 -

SELECTED ADJUSTED COSTS AND EXPENSES⁽²⁾


($ in millions) (Favorable)/Unfavorable	Fourth-Quarter						Full-Year
	2013		2012		% Change		2013		2012		% Change
	2013		2012		Total	Oper.	2013		2012		Total	Oper.
Cost of Sales⁽²⁾	$ 2,672		$ 2,686		(1%)	5%	$ 9,273		$ 9,492		(2%)	2%
Percent of Revenues⁽²⁾	19.8	%	19.3	%	N/A	N/A	18.0	%	17.4	%	N/A	N/A
SI&A Expenses⁽²⁾	4,093		4,276		(4%)	(2%)	14,172		15,029		(6%)	(5%)
R&D Expenses⁽²⁾	1,790		1,884		(5%)	(4%)	6,554		6,958		(6%)	(6%)
Total	$ 8,555		$ 8,846		(3%)	—	$ 29,999		$ 31,479		(5%)	(3%)

Effective Tax Rate⁽²⁾	27.7	%	29.7	%			27.5	%	28.7	%

2014 FINANCIAL GUIDANCE⁽⁶⁾

Pfizer's 2014 financial guidance is summarized below.




Adjusted Revenues⁽²⁾	$49.2 to $51.2 billion
Adjusted Cost of Sales⁽²⁾ as a Percentage of Adjusted Revenues⁽²⁾	19.0% to 20.0%
Adjusted SI&A Expenses⁽²⁾	$13.5 to $14.5 billion
Adjusted R&D Expenses⁽²⁾	$6.4 to $6.9 billion
Adjusted Other (Income)/Deductions⁽²⁾	Approximately $100 million
Effective Tax Rate on Adjusted Income⁽²⁾	Approximately 27.0%
Reported Diluted EPS⁽¹⁾	$1.57 to $1.72
Adjusted Diluted EPS⁽²⁾	$2.20 to $2.30

EXECUTIVE COMMENTARY

Ian Read, Chairman and Chief Executive Officer, stated, “The just-completed year was highlighted by solid financial performance and shareholder-friendly capital allocation, a strengthening of our innovative core as well as the formation of our new commercial structure designed to enable each business to have a sharper focus on its distinct market opportunities and challenges.”

“We enter 2014 with confidence in the competitive positioning of our commercial businesses, the prospects for our recently launched products and the strength of our research pipeline. We remain focused on those areas and opportunities we believe will continue to create value for our shareholders, and we seek to identify additional opportunities that will strengthen our innovative and established pharmaceutical businesses as well as our Consumer business. We will focus on advancing science and innovation to deliver new therapies in areas with

- 2 -

unmet need and ensuring our shareholders' capital is allocated toward the most attractive opportunities for value creation.”

Mr. Read continued, “During 2014, we expect to report on several, important clinical data readouts for our mid- and late-stage pipeline compounds. In the near term, we expect to report top-line results for the Phase 2 study for palbociclib in patients with post-menopausal, ER-positive, advanced breast cancer and for the CAPiTA study for Prevnar 13 in adults age 65 and older. In addition, we anticipate data presentations at upcoming medical conferences of Phase 2b data for bococizumab, our PCSK9 inhibitor for LDL cholesterol reduction, and Phase 2a data for our staphylococcus aureus vaccine. During the second quarter, we anticipate reporting top-line results for two pivotal Phase 3 studies for Xeljanz in psoriasis.”

“We see attractive opportunities globally to deliver value to patients, payors and other stakeholders through a combination of innovative, established and over-the-counter pharmaceutical products. I believe we have the business structure, leadership team and financial capability firmly in place to facilitate our continued success,” Mr. Read concluded.

Frank D’Amelio, Chief Financial Officer, stated, “For full-year 2013, I am pleased with our financial performance, our strategic accomplishments and our ability to continue delivering shareholder value through prudent capital allocation. Regarding our financial performance, we achieved or exceeded all elements of our 2013 financial guidance despite an operating environment that remains challenging. We completed two important strategic initiatives in 2013: the separation of our Animal Health business through the disposition of Zoetis⁽³⁾, and the formation of the new commercial structure that was successfully implemented at the start of 2014. Finally, we delivered significant shareholder value through share repurchases and dividends. With our strong operating cash flow as well as the proceeds generated from the separations of our Nutrition and Animal Health businesses, we repurchased $16.3 billion of our common stock in 2013. As a result of those share repurchases as well as Pfizer common stock tendered in the Zoetis⁽³⁾ exchange offer, we reduced the number of shares of outstanding common stock by approximately one billion, or 13%, in 2013 compared to year-end 2012. In addition, we paid $6.6 billion in dividends. In total, we returned approximately $23 billion to shareholders through share repurchases and dividends in 2013.”

“We are also providing our 2014 financial guidance, including ranges for adjusted revenues⁽²⁾ of $49.2 to $51.2 billion and for adjusted diluted EPS⁽²⁾ of $2.20 to $2.30. Our guidance for adjusted revenues⁽²⁾ reflects the anticipated negative impact of approximately $3.0 billion due to recent and expected product losses of exclusivity, as well as the expiration and near-term termination of certain collaboration agreements that continue to significantly negatively impact alliance revenue, partially offset by anticipated revenue growth from certain other products. We expect adjusted R&D expenses⁽²⁾ to be between $6.4 billion and $6.9 billion, which reflects the late-2013 and early-2014 initiations of Phase 3 clinical programs for certain pipeline compounds. Lastly, our reported⁽¹⁾ and adjusted⁽²⁾ diluted EPS guidance reflects anticipated share repurchases totaling approximately $5

- 3 -

billion this year. These planned repurchases will more than offset the potential dilution related to employee compensation programs,” concluded Mr. D’Amelio.

QUARTERLY FINANCIAL HIGHLIGHTS (Fourth-Quarter 2013 vs. Fourth-Quarter 2012)

▪

Reported revenues⁽¹⁾ decreased $333 million, or 2%, which reflects operational growth of $64 million, or 1%, and the unfavorable impact of foreign exchange of $397 million, or 3%. The operational increase was primarily due to the strong growth of Lyrica, Inlyta and Xalkori globally, Enbrel outside of North America, as well as Celebrex, Eliquis and Xeljanz, primarily in the U.S. In addition, fourth-quarter 2013 reported revenues⁽¹⁾ included $65 million from the transitional manufacturing and supply agreements with Zoetis⁽³⁾. Revenues were negatively impacted primarily by the expiration on October 31, 2013 of the collaboration agreement for Enbrel in North America, continued erosion for branded Lipitor in developed Europe and certain other developed markets, the ongoing expiration of the Spiriva collaboration in certain countries, other product losses of exclusivity in certain markets, decreased government purchases of Prevnar in certain emerging markets, and various other events.


▪	Business unit revenues were impacted by the following:

–

Primary Care: Revenues declined 8% operationally, primarily due to the shift in the reporting of Lipitor revenues in developed Europe and Australia to the Established Products unit beginning January 1, 2013, as well as certain other product losses of exclusivity in various markets, including Viagra in most major European markets in June 2013 and Lyrica in Canada in February 2013, and the termination of the co-promotion agreement for Aricept in Japan in December 2012. Additionally, in the U.S. and certain European countries, the co-promotion collaboration for Spiriva is in its final year, which, per the terms of the collaboration agreement, has resulted in a decline in Pfizer’s share of Spiriva revenues; the agreement has terminated in certain other countries. These declines were partially offset by the strong operational performance of Lyrica in developed markets as well as Celebrex, Eliquis and Premarin, primarily in the U.S.

–

Specialty Care: Revenues decreased 5% operationally, primarily due to the expiration of the collaboration agreement for Enbrel in North America on October 31, 2013; for a 36-month period thereafter, Pfizer is entitled to royalty payments that are expected to be significantly less than the share of Enbrel profits prior to the expiration of the collaboration agreement, and those royalty payments are and will be included in Other (income)/deductions–net rather than in Revenues. Revenues were also negatively impacted by the shift in the reporting of Geodon and Revatio revenues in the U.S. and Xalabrands revenues in developed Europe and Australia to the Established Products unit beginning January 1, 2013. These declines were partially offset by the growth of Prevnar, Enbrel

- 4 -

outside of North America as well as Xeljanz and the hemophilia portfolio (BeneFIX and ReFacto AF/Xyntha) in the U.S.

–

Emerging Markets: Revenues grew 9% operationally, primarily due to volume growth in China, most notably for Lipitor, which was partially offset by the impact of the transfer of certain product rights to the Pfizer-Hisun joint venture in first-quarter 2013. Revenues were also negatively impacted by decreased government purchases of Prevnar as well as government cost-containment measures in certain other emerging markets.

–

Established Products: Revenues increased 6% operationally. This performance was driven by the favorable impact of revenues from products in certain markets that were shifted to the Established Products unit from other business units beginning January 1, 2013, including Lipitor, Caduet and Xalbrands in developed Europe and Australia and Geodon in the U.S., as well as the contribution from the collaboration with Mylan Inc. to market generic drugs in Japan. Revenues were unfavorably impacted by the continued erosion of branded Lipitor in Japan due to generic competition and additional generic competition for Metaxalone/Skelaxin in the U.S.

–

Consumer Healthcare: Revenues increased 2% operationally, primarily due to strong emerging markets growth for core supplement products, including Centrum and Caltrate, as a result of several recent product launches and increased promotional activities in those markets, as well as growth of Emergen-C in the U.S. due to additional promotional activities. This growth was partially offset by a decline in revenues for pain management products in the U.S., primarily due to increased competition resulting from the return to the market of certain competing analgesic brands.

–

Oncology: Revenues increased 29% operationally, driven by the continued solid uptake of new products, most notably Inlyta and Xalkori in several major markets. Inlyta’s market share is stable in the U.S. and continues to increase in international developed markets as physician and patient feedback remains positive both in terms of efficacy and tolerability, and as pricing and reimbursement are being granted in additional developed Europe markets. Revenues were negatively impacted by the performance of Sutent due to increased competitive pressures in certain international developed markets as well as government cost-containment measures in certain European markets.

▪

Adjusted cost of sales, adjusted SI&A expenses and adjusted R&D expenses⁽²⁾ in the aggregate were flat operationally. Overall, they decreased $291 million, or 3%, primarily reflecting the favorable impact of foreign exchange and the benefits of cost-reduction and productivity initiatives, partially offset by higher adjusted cost of sales⁽²⁾ on an operational basis due to an unfavorable shift in product mix and adjusted SI&A expenses⁽²⁾ to support several new product launches.

- 5 -

▪

The effective tax rate on adjusted income⁽²⁾ declined 2.0 percentage points to 27.7% from 29.7%. This decline was primarily due to an increase in tax benefits compared to fourth-quarter 2012 related to audit settlements with foreign jurisdictions for multiple years and the extension of the U.S. research and development tax credit that was signed into law in January 2013, partially offset by a change in the jurisdictional mix of earnings.


▪	The diluted weighted-average shares outstanding declined by approximately 862 million shares, due to the company’s ongoing share repurchase program and the impact of the Zoetis⁽³⁾ exchange offer, which was completed on June 24, 2013.

▪

In addition to the aforementioned factors, fourth-quarter 2013 reported earnings were significantly unfavorably impacted by the non-recurrence of income from discontinued operations attributable to the company’s Animal Health and Nutrition businesses, including the gain on the sale of the Nutrition business, in the year-ago quarter. Reported earnings were favorably impacted by a lower effective tax rate, lower charges related to asset impairments and legal matters, and lower acquisition-related expenses. The effective tax rate on reported income⁽¹⁾ decreased in fourth-quarter 2013 in comparison with the year-ago quarter primarily due to an increase in tax benefits related to an audit settlement with the U.S. Internal Revenue Service as well as audit settlements with foreign jurisdictions for multiple years.

FULL-YEAR FINANCIAL HIGHLIGHTS (Full-Year 2013 vs. Full-Year 2012)

▪

Reported revenues⁽¹⁾ decreased $3.1 billion, or 6%, which reflects an operational decline of $1.9 billion, or 4%, and the unfavorable impact of foreign exchange of $1.2 billion, or 2%. In addition to the aforementioned factors that negatively impacted fourth-quarter 2013 revenues, full-year 2013 revenues were negatively impacted by erosion of branded Lipitor in the U.S. and decreased government purchases of Enbrel in certain emerging markets. Revenues were positively impacted by the operational growth of Lyrica, Celebrex, Inlyta and Xalkori globally, Eliquis and Xeljanz in the U.S., as well as the contribution from the collaboration with Mylan Inc. to market generic drugs in Japan. In addition, reported revenues⁽¹⁾ in full-year 2013 included $132 million from the transitional manufacturing and supply agreements with Zoetis⁽³⁾.

▪

Adjusted cost of sales, adjusted SI&A expenses and adjusted R&D expenses⁽²⁾ in the aggregate decreased $1.5 billion, or 5%, primarily reflecting the benefits of cost-reduction and productivity initiatives, the non-recurrence of a $250 million payment included in adjusted R&D expenses⁽²⁾ in third-quarter 2012 to obtain the exclusive global over-the-counter rights to Nexium, and the favorable impact of foreign exchange, partially offset by higher adjusted cost of sales⁽²⁾ on an operational basis due to an unfavorable shift in product mix and adjusted SI&A expenses⁽²⁾ to support several new product launches.

- 6 -


▪	The effective tax rate on adjusted income⁽²⁾ declined 1.2 percentage points to 27.5% from 28.7%. This decline was primarily due to an increase in tax benefits compared to 2012 related to audit settlements with foreign jurisdictions for multiple years and the extension of the U.S. research and development tax credit that was signed into law in January 2013.


▪	The diluted weighted-average shares outstanding declined by approximately 613 million shares, due to the company’s ongoing share repurchase program and the partial-year impact of the Zoetis⁽³⁾ exchange offer, which was completed on June 24, 2013.


▪	In addition to the aforementioned factors, full-year 2013 reported earnings were impacted by the following:

Favorable impacts:


–	the gain associated with the full disposition of Zoetis⁽³⁾ in second-quarter 2013;


–	income from a litigation settlement in second-quarter 2013 with Teva Pharmaceuticals Industries Ltd. and Sun Pharmaceutical Industries Ltd. for patent-infringement damages resulting from their “at-risk” launches of generic Protonix in the U.S.;


–	the gain associated with the transfer of certain product rights to Pfizer’s joint venture with Zhejiang Hisun Pharmaceuticals (Hisun) in China in first-quarter 2013; and


–	lower charges related to other legal matters, lower acquisition-related costs and lower expenses related to cost-reduction and productivity initiatives.

Unfavorable impacts:


–	the non-recurrence in full-year 2013 of the income from discontinued operations attributable to the company’s Nutrition business in 2012, including the gain on the sale of the Nutrition business in fourth-quarter 2012;


–	the non-recurrence after June 24, 2013 of the income from discontinued operations attributable to the company’s Animal Health business in 2012;


–	higher asset impairments and related charges; and


–	a higher effective tax rate. The effective tax rate on reported income⁽¹⁾ increased primarily due to a decrease in tax benefits related to certain audit settlements in multiple jurisdictions covering various periods and a change in the jurisdictional mix of earnings.

- 7 -

RECENT NOTABLE DEVELOPMENTS

Product Developments

▪

Viagra -- Pfizer settled its litigation against Teva Pharmaceuticals, USA Inc. (Teva) relating to Pfizer’s patent covering the use of Viagra to treat erectile dysfunction, which expires in April 2020 (including pediatric exclusivity). As a result of the settlement, Teva will be allowed to launch a generic version of Viagra in the U.S. on December 11, 2017, or earlier under certain circumstances. Teva will pay Pfizer a royalty for a license to produce its generic version. The terms of the settlement agreement are otherwise confidential.


▪	Xalkori -- The U.S. Food and Drug Administration (FDA) granted regular approval for the treatment of patients with metastatic ALK-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. Xalkori was previously granted accelerated approval in August 2011 due to the critical need for new agents for people living with ALK-positive NSCLC.


▪	Xeljanz


–	The FDA approved a supplemental New Drug Application (sNDA) to include additional patient-reported outcomes data in the label for adults with moderately to severely active rheumatoid arthritis. These additional data show improvement in patients receiving Xeljanz based on health-related outcome measures reported by patients.

–

The top-line results were announced from the first two (OPT Compare and OPT Retreatment) of five Phase 3 clinical trials in adults with moderate-to-severe chronic plaque psoriasis. In OPT Compare, Xeljanz met the primary endpoint of non-inferiority to high-dose Enbrel at the 10 mg twice-daily (BID) dose, but did not at the 5 mg BID dose. In OPT Retreatment, Xeljanz met the primary efficacy endpoints at the 5 and 10 mg BID doses by demonstrating that a greater proportion of patients continuing Xeljanz treatment maintained their response during the treatment-withdrawal phase compared to patients who switched to placebo. Additionally, among patients who lost an adequate response, many were able to recapture their response upon retreatment with Xeljanz. No new safety signals were observed in these two studies.

▪

Eliquis -- The FDA accepted for review an sNDA for Eliquis for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is August 25, 2014. Additionally, the European Medicines Agency accepted for review an application for Eliquis for the treatment of DVT and PE, and prevention of recurrent DVT and PE.

- 8 -


▪	Duavee -- The FDA approved Duavee (0.45 mg/20 mg tablets), a novel therapy for women with a uterus, for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis. Duavee is expected to be available in the U.S. in February 2014.


▪	Embeda -- The FDA approved a Prior Approval Supplement for Embeda Extended Release Capsules CII. The Prior Approval Supplement included an update to the Embeda manufacturing process that addressed the pre-specified stability requirement that led to the voluntary recall of Embeda from the market in March 2011. Pfizer anticipates product availability beginning in the second quarter of 2014.

▪

Remoxy -- Pfizer will continue the development program for Remoxy Extended-Release Capsules CII. Having achieved technical milestones related to manufacturing and following guidance received from the FDA in 2013, Pfizer is proceeding with the additional clinical studies and other actions required to address the Complete Response Letter received in June 2011. As previously disclosed, the complete response submission is not expected to occur prior to mid-2015.


▪	Lipitor Over-the-Counter (OTC) -- A Phase 3 "actual use" trial intended to simulate the OTC use of atorvastatin calcium 10 mg began enrolling patients.

Pipeline Developments


▪	Palbociclib

–

A Phase 3 trial (PENELOPE-B) in early-stage breast cancer began enrolling patients. This is a randomized global study that will evaluate palbociclib in combination with endocrine therapy versus placebo plus endocrine therapy in prolonging investigator-assessed, invasive disease-free survival in women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) early-stage breast cancer with high risk of relapse after neoadjuvant chemotherapy. This trial is sponsored by the German Breast Group, a leading cooperative group with extensive experience conducting clinical trials in breast cancer, in collaboration with Pfizer.


–	Pfizer entered into an agreement with GSK to explore the anti-cancer efficacy and the safety of GSK’s trametinib (GSK1120212) combined with palbociclib in a Phase I/II study in patients with advanced/metastatic melanoma. The two companies will collaborate on the study, which GSK will conduct.

▪

Dacomitinib -- Pfizer announced top-line results from two Phase 3 studies of dacomitinib in patients with previously treated advanced NSCLC. Neither study met its primary endpoint. In the ARCHER 1009 trial, dacomitinib did not demonstrate statistically significant improvement in progression-free survival (PFS) when compared with erlotinib and in the BR.26 trial, dacomitinib did not prolong overall survival versus

- 9 -

placebo. A third Phase 3 trial, ARCHER 1050, is ongoing and evaluating PFS of dacomitinib in treatment-naïve patients with EGFR-mutant advanced NSCLC; results are expected in 2015.

▪

ALO-02 -- Pfizer announced top-line results from a Phase 3 study of ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic low back pain. In this study, ALO-02 met the primary efficacy endpoint, demonstrating a statistically significant difference from placebo in the mean change in the daily average pain numerical rating scale scores from baseline to the final two weeks of the double-blind treatment period.


▪	Tafamidis -- Pfizer initiated a global Phase 3 program for tafamidis in transthyretin cardiomyopathy (TTR-CM), the first study of its kind in this rare, progressive and universally fatal disease. Tafamidis is approved for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) in the European Union and Japan under the trade name Vyndaqel.

▪

Bococizumab (RN316) -- The Phase 3 program was initiated for this PCSK9 monoclonal antibody to lower LDL cholesterol. This is a global program expected to involve more than 22,000 patients, which includes multiple lipid-lowering studies as well as two cardiovascular outcomes studies. This program includes the broadest range of high-risk patients including a focus on patients in greatest need of LDL-lowering.


▪	Ertugliflozin -- Pfizer in collaboration with Merck initiated a Phase 3 program for this SGLT2 inhibitor for the treatment of type 2 diabetes.

▪

Tanezumab -- Pfizer entered into a collaboration agreement with Eli Lilly & Company (Lilly) to jointly develop and globally commercialize tanezumab, which provides that Pfizer and Lilly will equally share product-development expenses as well as potential revenues and certain product-related costs. The tanezumab program currently is subject to a partial clinical hold by the FDA pending submission of nonclinical data to the FDA. Pfizer now anticipates submitting that data by the end of 2014.

Other Developments


▪	Pfizer successfully implemented its previously announced plans to internally separate its commercial operations into three businesses at the start of the 2014 fiscal year. The company remains on track to provide greater financial transparency for each of these businesses beginning with first-quarter 2014 financial results.

- 10 -

For additional details, see the attached financial schedules, product revenue tables and disclosure notice.


(1)	“Reported Revenues” is defined as revenues in accordance with U.S. generally accepted accounting principles (GAAP). “Reported Net Income” is defined as net income attributable to Pfizer Inc. in accordance with U.S. GAAP. “Reported Diluted EPS” is defined as reported diluted EPS attributable to Pfizer Inc. common shareholders in accordance with U.S. GAAP.

(2)

“Adjusted Income” and its components and “Adjusted Diluted Earnings Per Share (EPS)” are defined as reported U.S. GAAP net income⁽¹⁾ and its components and reported diluted EPS⁽¹⁾ excluding purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items. Adjusted Revenues, Adjusted Cost of Sales, Adjusted Selling, Informational and Administrative (SI&A) expenses, Adjusted Research and Development (R&D) expenses and Adjusted Other (Income)/Deductions are income statement line items prepared on the same basis, and, therefore, components of the overall adjusted income measure. As described under Adjusted Income in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section of Pfizer’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 29, 2013, management uses adjusted income, among other factors, to set performance goals and to measure the performance of the overall company. We believe that investors’ understanding of our performance is enhanced by disclosing this measure. See the accompanying reconciliations of certain GAAP reported to non-GAAP adjusted information for the fourth quarter and twelve months ended 2013 and 2012, as well as reconciliations of full-year 2014 guidance for adjusted income and adjusted diluted EPS to full-year 2014 guidance for reported net income⁽¹⁾ and reported diluted EPS⁽¹⁾. The adjusted income and its components and adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS.


(3)	On June 24, 2013, we completed the full disposition of Zoetis, Inc. (Zoetis) and recognized a gain of approximately $10.3 billion, net of tax, in Discontinued operations––net of tax for the twelve months ended December 31, 2013. The financial results of our Animal Health business are reported as Discontinued operations––net of tax through June 24, 2013, the date of disposal.


(4)	For a description of the revenues in each business unit, see Note 13 to Pfizer’s condensed consolidated financial statements included in Pfizer’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 29, 2013.


(5)	Other represents revenues generated from Pfizer CentreSource, Pfizer’s contract manufacturing and bulk pharmaceutical chemical sales organization, and includes, in 2013, revenues related to our transitional manufacturing and supply agreements with Zoetis⁽³⁾.


(6)	The 2014 financial guidance reflects the following:


▪	Does not assume the completion of any business development transactions not completed as of December 31, 2013, including any one-time upfront payments associated with such transactions.


▪	Excludes the potential effects of the resolution of litigation-related matters not substantially resolved as of December 31, 2013.


▪	Exchange rates assumed are as of mid-January 2014.


▪	Assumes diluted weighted-average shares outstanding of approximately 6.4 billion shares.


▪	Revenues and cost of sales from the transitional manufacturing and supply agreements with Zoetis⁽³⁾ have been excluded from the applicable Adjusted components of the financial guidance.

- 11 -


▪	Reconciliation of the 2014 Adjusted Income⁽²⁾ and Adjusted Diluted EPS⁽²⁾ guidance to the 2014 Reported Net Income Attributable to Pfizer Inc. and Reported Diluted EPS Attributable to Pfizer Inc. common shareholders guidance:




($ in billions, except per share amounts)
Income/(Expense)	Net Income	Diluted EPS
Adjusted income/diluted EPS⁽²⁾ guidance	$14.1 - $14.8	$2.20 - $2.30
Purchase accounting impacts of transactions completed as of December 31, 2013	(2.8)	(0.43)
Restructuring and implementation costs	(1.0 - 1.3)	(0.15 - 0.20)
Reported net income attributable to Pfizer Inc./diluted EPS⁽¹⁾guidance	$10.0 - $11.0	$1.57 - $1.72



Contacts:	Media		Investors
	Joan Campion	212.733.2798	Chuck Triano	212.733.3901
			Ryan Crowe	212.733.8160

- 12 -

PFIZER INC. AND SUBSIDIARY COMPANIES

CONSOLIDATED STATEMENTS OF INCOME⁽¹⁾

(UNAUDITED)

(millions, except per common share data)



	Fourth-Quarter					% Incr. /	Full-Year					% Incr. /
	2013			2012		(Decr.)	2013			2012		(Decr.)
Revenues	$	13,558		$	13,891	(2)	$	51,584		$	54,657	(6)
Costs and expenses:
Cost of sales⁽²⁾	2,794			2,753		1	9,586			9,821		(2)
Selling, informational and administrative expenses⁽²⁾	4,152			4,337		(4)	14,355			15,171		(5)
Research and development expenses⁽²⁾	1,811			2,021		(10)	6,678			7,482		(11)
Amortization of intangible assets⁽³⁾	1,123			1,220		(8)	4,599			5,109		(10)
Restructuring charges and certain acquisition-related costs	635			725		(12)	1,182			1,810		(35)
Other (income)/deductions––net⁽⁴⁾	(18		)	758		*	(532		)	4,022		*

Income from continuing operations before provision for taxes on income	3,061			2,077		47	15,716			11,242		40
Provision for taxes on income⁽⁵⁾	430			599		(28)	4,306			2,221		94
Income from continuing operations	2,631			1,478		78	11,410			9,021		26
Discontinued operations––net of tax	(57		)	4,843		*	10,662			5,577		91
Net income before allocation to noncontrolling interests	2,574			6,321		(59)	22,072			14,598		51
Less: Net income attributable to noncontrolling interests	6			6		—	69			28		*
Net income attributable to Pfizer Inc.	$	2,568		$	6,315	(59)	$	22,003		$	14,570	51

Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders	$	0.41		$	0.20	*	$	1.67		$	1.21	38
Discontinued operations––net of tax	(0.01		)	0.66		*	1.56			0.75		*
Net income attributable to Pfizer Inc. common shareholders	$	0.40		$	0.86	(53)	$	3.23		$	1.96	65

Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders	$	0.40		$	0.20	100	$	1.65		$	1.20	38
Discontinued operations––net of tax	(0.01		)	0.65		*	1.54			0.74		*
Net income attributable to Pfizer Inc. common shareholders	$	0.39		$	0.85	(54)	$	3.19		$	1.94	64
Weighted-average shares used to calculate earnings per common share:
Basic	6,443			7,319			6,813			7,442
Diluted	6,533			7,395			6,895			7,508

* Calculation not meaningful.

See next pages for notes (1) through (5).

Certain amounts and percentages may reflect rounding adjustments.

- 13 -

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)


(1)	The financial statements present the three and twelve months ended December 31, 2013 and 2012. Subsidiaries operating outside the United States are included for the three and twelve months ended November 30, 2013 and 2012.

On June 24, 2013, we completed the full disposition of our Animal Health business (Zoetis) and recognized a gain of approximately $10.3 billion, net of tax, in Discontinued operations––net of tax for the twelve months ended December 31, 2013. The operating results of this business are reported as Discontinued operations––net of tax through June 24, 2013, the date of disposal.

On November 30, 2012, we completed the sale of our Nutrition business and recognized a gain of approximately $4.8 billion, net of tax, in Discontinued operations––net of tax for the three and twelve months ended December 31, 2012. The operating results of this business are reported as Discontinued operations––net of tax through November 30, 2012, the date of disposal.


(2)	Exclusive of amortization of intangible assets, except as discussed in footnote (3) below.

(3)

Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization expense related to intangible assets that are associated with a single function is included in Cost of sales, Selling, informational and administrative expenses or Research and development expenses, as appropriate.


(4)	Other (income)/deductions––net includes the following:




	Fourth-Quarter						Full-Year
(millions of dollars)	2013			2012			2013			2012
Interest income^(a)	$	(112	)	$	(107	)	$	(403	)	$	(382	)
Interest expense^(a)	347			373			1,414			1,522
Net interest expense	235			266			1,011			1,140
Royalty-related income^(b)	(218		)	(108		)	(523		)	(451		)
Patent litigation settlement income^(c)	—			—			(1,342		)	—
Other legal matters, net^(d)	129			206			35			2,220
Gain associated with the transfer of certain product rights to an equity-method investment^(e)	—			—			(459		)	—
Net gains on asset disposals^(f)	(220		)	(7		)	(320		)	(52		)
Certain asset impairments and related charges^(g)	133			366			1,101			890
Costs associated with the Zoetis IPO^(h)	—			32			18			125
Other, net	(77		)	3			(53		)	150
Other (income)/deductions––net	$	(18	)	$	758		$	(532	)	$	4,022

- 14 -

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)


(a)	Interest income increased in fourth-quarter and full-year 2013 due to higher cash and investment balances. Interest expense decreased in fourth-quarter and full-year 2013 due to lower outstanding debt, refinancings and lower rates, and the benefit of the conversion of some fixed-rate liabilities to floating-rate liabilities.


(b)	Royalty-related income increased in fourth-quarter and full-year 2013 due to royalties earned on sales of Enbrel in North America after October 31, 2013. On that date, our collaboration agreement for Enbrel in North America expired, and we became entitled to royalties for a 36-month period.


(c)	Reflects income from a litigation settlement with Teva Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries Ltd. for patent-infringement damages resulting from their "at-risk" launches of generic Protonix in the U.S.


(d)	In full-year 2012, primarily includes a $491 million charge related to the resolution of an investigation by the U.S. Department of Justice into Wyeth's historical promotional practices in connection with Rapamune, a $450 million settlement of a lawsuit by Brigham Young University related to Celebrex, and charges for hormone-replacement therapy litigation and Chantix litigation.


(e)	Represents the gain associated with the transfer of certain product rights to Pfizer's 49%-owned equity-method investment in China.


(f)	In fourth-quarter and full-year 2013, includes a gain of $125 million on the sale of a portion of our in-licensed generic sterile injectibles portfolio.

(g)

In full-year 2013, primarily includes impairment charges related to developed technology (for use in the development of bone and cartilage) acquired in connection with our acquisition of Wyeth, and in-process research and development (IPR&D) compounds. Full-year 2013 also includes a loss on an option to acquire the remaining interest in a 40%-owned generics company in Brazil (approximately $220 million). In fourth-quarter and full-year 2012, primarily includes impairment charges related to certain intangible assets acquired in connection with our acquisitions of Wyeth and King Pharmaceuticals Inc. (King), including IPR&D intangible assets.


(h)	Costs incurred in connection with the initial public offering (IPO) of an approximate 19.8% ownership interest in Zoetis. Includes expenditures for banking, legal, accounting and similar services.

(5)

The Provision for taxes on income for fourth-quarter and full-year 2013 was favorably impacted by U.S. tax benefits of approximately $430 million, representing tax and interest, resulting from a settlement with the U.S. Internal Revenue Service (IRS) with respect to audits of the Wyeth tax returns for the years 2006 through date of acquisition. Full-year 2013 was also favorably impacted by international tax benefits of approximately $470 million, most of which occurred in the fourth quarter, representing tax and interest, resulting from the resolution of certain tax positions pertaining to prior years with various foreign tax authorities and from the expiration of certain statutes of limitations, as well as the extension of the U.S. research and development tax credit that was signed into law in January 2013. The Provision for taxes on income for full-year 2012 was favorably impacted by a $1.1 billion settlement (representing tax and interest) with the IRS related to audits for multiple tax years, as well as approximately $300 million related to the resolution of foreign audits pertaining to multiple tax years, partially offset by the unfavorable impact of the non-deductibility of a legal charge related to Rapamune.

- 15 -

PFIZER INC. AND SUBSIDIARY COMPANIES

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

CERTAIN LINE ITEMS

(UNAUDITED)

(millions of dollars, except per common share data)



	Quarter Ended December 31, 2013
	GAAP Reported⁽¹⁾			Purchase Accounting Adjustments			Acquisition-Related Costs⁽²⁾			Discontinued Operations			Certain Significant Items⁽³⁾			Non-GAAP Adjusted⁽⁴⁾
Revenues	$	13,558		$	—		$	—		$	—		$	(65	)	$	13,493
Cost of sales⁽⁵⁾	2,794			7			(15		)	—			(114		)	2,672
Selling, informational and administrative expenses⁽⁵⁾	4,152			3			—			—			(62		)	4,093
Research and development expenses⁽⁵⁾	1,811			2			—			—			(23		)	1,790
Amortization of intangible assets⁽⁶⁾	1,123			(1,086		)	—			—			—			37
Restructuring charges and certain acquisition-related costs	635			—			(97		)	—			(538		)	—
Other (income)/deductions––net	(18		)	17			—			—			(200		)	(201		)
Income from continuing operations before provision for taxes on income	3,061			1,057			112			—			872			5,102
Provision for taxes on income	430			257			35			—			689			1,411
Income from continuing operations	2,631			800			77			—			183			3,691
Discontinued operations––net of tax	(57		)	—			—			57			—			—
Net income attributable to noncontrolling interests	6			—			—			(1		)	—			5
Net income attributable to Pfizer Inc.	2,568			800			77			58			183			3,686
Earnings per common share attributable to Pfizer Inc.––diluted	0.39			0.12			0.01			0.01			0.03			0.56



	Twelve Months Ended December 31, 2013
	GAAP Reported⁽¹⁾			Purchase Accounting Adjustments			Acquisition-Related Costs⁽²⁾			Discontinued Operations			Certain Significant Items⁽³⁾			Non-GAAP Adjusted⁽⁴⁾
Revenues	$	51,584		$	—		$	—		$	—		$	(132	)	$	51,452
Cost of sales⁽⁵⁾	9,586			23			(116		)	—			(220		)	9,273
Selling, informational and administrative expenses⁽⁵⁾	14,355			8			(8		)	—			(183		)	14,172
Research and development expenses⁽⁵⁾	6,678			3			—			—			(127		)	6,554
Amortization of intangible assets⁽⁶⁾	4,599			(4,438		)	—			—			—			161
Restructuring charges and certain acquisition-related costs	1,182			—			(252		)	—			(930		)	—
Other (income)/deductions––net	(532		)	60			—			—			636			164
Income from continuing operations before provision for taxes on income	15,716			4,344			376			—			692			21,128
Provision for taxes on income	4,306			1,198			(7		)	—			313			5,810
Income from continuing operations	11,410			3,146			383			—			379			15,318
Discontinued operations––net of tax	10,662			—			—			(10,662		)	—			—
Net income attributable to noncontrolling interests	69			—			—			(39		)	—			30
Net income attributable to Pfizer Inc.	22,003			3,146			383			(10,623		)	379			15,288
Earnings per common share attributable to Pfizer Inc.––diluted	3.19			0.46			0.06			(1.54		)	0.05			2.22

See end of tables for notes (1) through (6).

Certain amounts may reflect rounding adjustments.

- 16 -

PFIZER INC. AND SUBSIDIARY COMPANIES

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

CERTAIN LINE ITEMS

(UNAUDITED)

(millions of dollars, except per common share data)




	Quarter Ended December 31, 2012
	GAAP Reported⁽¹⁾		Purchase Accounting Adjustments			Acquisition-Related Costs⁽²⁾			Discontinued Operations			Certain Significant Items⁽³⁾			Non-GAAP Adjusted⁽⁴⁾
Revenues	$	13,891	$	—		$	—		$	—		$	—		$	13,891
Cost of sales⁽⁵⁾	2,753		5			(53		)	—			(19		)	2,686
Selling, informational and administrative expenses⁽⁵⁾	4,337		8			(2		)	—			(67		)	4,276
Research and development expenses⁽⁵⁾	2,021		(1		)	(1		)	—			(135		)	1,884
Amortization of intangible assets⁽⁶⁾	1,220		(1,198		)	—			—			—			22
Restructuring charges and certain acquisition-related costs	725		—			(252		)	—			(473		)	—
Other (income)/deductions––net	758		(6		)	—			—			(561		)	191
Income from continuing operations before provision for taxes on income	2,077		1,192			308			—			1,255			4,832
Provision for taxes on income	599		329			47			—			460			1,435
Income from continuing operations	1,478		863			261			—			795			3,397
Discontinued operations––net of tax	4,843		—			—			(4,843		)	—			—
Net income attributable to noncontrolling interests	6		—			—			—			—			6
Net income attributable to Pfizer Inc.	6,315		863			261			(4,843		)	795			3,391
Earnings per common share attributable to Pfizer Inc.––diluted	0.85		0.12			0.04			(0.65		)	0.11			0.46



	Twelve Months Ended December 31, 2012
	GAAP Reported⁽¹⁾		Purchase Accounting Adjustments			Acquisition-Related Costs⁽²⁾			Discontinued Operations			Certain Significant Items⁽³⁾			Non-GAAP Adjusted⁽⁴⁾
Revenues	$	54,657	$	—		$	—		$	—		$	—		$	54,657
Cost of sales⁽⁵⁾	9,821		(1		)	(258		)	—			(70		)	9,492
Selling, informational and administrative expenses⁽⁵⁾	15,171		11			(9		)	—			(144		)	15,029
Research and development expenses⁽⁵⁾	7,482		3			(6		)	—			(521		)	6,958
Amortization of intangible assets⁽⁶⁾	5,109		(4,924		)	—			—			—			185
Restructuring charges and certain acquisition-related costs	1,810		—			(673		)	—			(1,137		)	—
Other (income)/deductions––net	4,022		6			—			—			(3,167		)	861
Income from continuing operations before provision for taxes on income	11,242		4,905			946			—			5,039			22,132
Provision for taxes on income	2,221		1,343			203			—			2,588			6,355
Income from continuing operations	9,021		3,562			743			—			2,451			15,777
Discontinued operations––net of tax	5,577		—			—			(5,577		)	—			—
Net income attributable to noncontrolling interests	28		—			—			—			—			28
Net income attributable to Pfizer Inc.	14,570		3,562			743			(5,577		)	2,451			15,749
Earnings per common share attributable to Pfizer Inc.––diluted	1.94		0.47			0.10			(0.74		)	0.33			2.10

See end of tables for notes (1) through (6).

Certain amounts may reflect rounding adjustments.

EPS amounts may not add due to rounding.

- 17 -

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

CERTAIN LINE ITEMS

(UNAUDITED)


(1)	The financial statements present the three and twelve months ended December 31, 2013 and 2012. Subsidiaries operating outside the United States are included for the three and twelve months ended November 30, 2013 and 2012.


(2)	Acquisition-related costs include the following:




	Fourth-Quarter						Full-Year
(millions of dollars)	2013			2012			2013		2012
Restructuring charges^(a)	$	60		$	149		$	108	$	291
Transaction costs^(a)	—			1			—		1
Integration costs^(a)	37			102			144		381
Additional depreciation––asset restructuring^(b)	15			56			124		273
Total acquisition-related costs––pre-tax	112			308			376		946
Income taxes^(c)	(35		)	(47		)	7		(203		)
Total acquisition-related costs––net of tax	$	77		$	261		$	383	$	743

(a)

Restructuring charges include employee termination costs, asset impairments and other exit costs associated with business combinations. Transaction costs represent external costs directly related to acquired businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. All of these costs and charges are included in Restructuring charges and certain acquisition-related costs.

(b)

Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions related to acquisitions. Included in Cost of sales for the three months ended December 31, 2013. Included in Cost of sales ($116 million) and Selling, informational and administrative expenses ($8 million) for the twelve months ended December 31, 2013. Included in Cost of sales ($53 million), Selling, informational and administrative expenses ($2 million) and Research and development expenses ($1 million) for the three months ended December 31, 2012. Included in Cost of sales ($258 million), Selling, informational and administrative expenses ($9 million) and Research and development expenses ($6 million) for the twelve months ended December 31, 2012.


(c)	Included in Provision for taxes on income. Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction’s applicable tax rate. The full-year 2013 also includes the unfavorable

- 18 -

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

CERTAIN LINE ITEMS

(UNAUDITED)

impact of the remeasurement of certain deferred tax liabilities resulting from plant network restructuring activities.


(3)	Certain significant items include the following:




	Fourth-Quarter						Full-Year
(millions of dollars)	2013			2012			2013			2012
Restructuring charges^(a)	$	538		$	473		$	930		$	1,137
Implementation costs and additional depreciation––asset restructuring^(b)	128			207			398			692
Patent litigation settlement income^(c)	—			—			(1,342		)	—
Other legal matters, net^(d)	120			210			21			2,191
Gain associated with the transfer of certain product rights to an equity-method investment^(e)	—			—			(459		)	—
Certain asset impairments and related charges^(f)	130			369			1,059			875
Costs associated with the Zoetis IPO^(g)	—			32			18			125
Income associated with the transitional manufacturing and supply agreements with Zoetis^(h)	(6		)	—			(16		)	—
Other⁽ⁱ⁾	(38		)	(36		)	83			19
Total certain significant items––pre-tax	872			1,255			692			5,039
Income taxes^(j)	(689		)	(460		)	(313		)	(2,588		)
Total certain significant items––net of tax	$	183		$	795		$	379		$	2,451


(a)	Primarily related to our cost-reduction and productivity initiatives. Included in Restructuring charges and certain acquisition-related costs.

(b)

Primarily related to our cost-reduction and productivity initiatives. Included in Cost of sales ($55 million), Selling, informational and administrative expenses ($50 million) and Research and development expenses ($23 million) for the three months ended December 31, 2013. Included in Cost of sales ($115 million), Selling, informational and administrative expenses ($156 million) and Research and development expenses ($127 million) for the twelve months ended December 31, 2013. Included in Cost of sales ($8 million), Selling, informational and administrative expenses ($64 million) and Research and development expenses ($135 million) for the three months ended December 31, 2012. Included in Cost of sales ($30 million), Selling, informational and administrative expenses ($141 million) and Research and development expenses ($521 million) for the twelve months ended December 31, 2012.


(c)	Included in Other (income)/deductions––net. Reflects income from a litigation settlement with Teva Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries Ltd. for patent-infringement damages resulting from their "at-risk" launches of generic Protonix in the U.S.

(d)

Primarily included in Other (income)/deductions––net. In full-year 2012, primarily includes a $491 million charge related to the resolution of an investigation by the U.S. Department of Justice into Wyeth's historical promotional practices in connection with Rapamune, a $450 million settlement of a lawsuit by Brigham Young University related to Celebrex, and charges for hormone-replacement therapy litigation and Chantix litigation.

- 19 -

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

CERTAIN LINE ITEMS

(UNAUDITED)


(e)	Included in Other (income)/deductions––net. Represents the gain associated with the transfer of certain product rights to Pfizer's 49%-owned equity-method investment in China.

(f)

Primarily included in Other (income)/deductions––net. In full-year 2013, primarily includes impairment charges related to developed technology (for use in the development of bone and cartilage) acquired in connection with our acquisition of Wyeth, and in-process research and development (IPR&D) compounds. Full-year 2013 also includes a loss on an option to acquire the remaining interest in a 40%-owned generics company in Brazil (approximately $220 million). In fourth-quarter and full-year 2012, primarily includes impairment charges related to certain intangible assets acquired in connection with our acquisitions of Wyeth and King, including IPR&D intangible assets.


(g)	Included in Other (income)/deductions––net. Costs incurred in connection with the initial public offering of an approximate 19.8% ownership interest in Zoetis. Includes expenditures for banking, legal, accounting and similar services.


(h)	Included in Revenues ($65 million) and Cost of sales ($59 million) for the three months ended December 31, 2013. Included in Revenues ($132 million) and Cost of sales ($116 million) for the twelve months ended December 31, 2013.


(i)	Primarily included in Other (income)/deductions––net.

(j)

Included in Provision for taxes on income. Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction’s applicable tax rate. The fourth quarter of 2013 was favorably impacted by U.S. tax benefits of approximately $430 million, representing tax and interest, resulting from a settlement with the U.S. Internal Revenue Service (IRS) with respect to audits of the Wyeth tax returns for the years 2006 through date of acquisition. The full-year 2013 was unfavorably impacted by (i) the tax liability associated with the patent litigation settlement income, (ii) the non-deductibility of goodwill derecognized and the jurisdictional mix of the other intangible assets divested as part of the transfer of certain product rights to Pfizer's 49%-owned equity-method investment in China, and (iii) the non-deductibility of the loss on an option to acquire the remaining interest in a 40%-owned generics company in Brazil since we expect to retain the investment indefinitely, and was favorably impacted by the aforementioned fourth quarter tax settlement. In full-year 2012, includes a settlement with the IRS related to audits for multiple tax years that favorably impacted GAAP Reported net income by $1.1 billion, representing tax and interest.

(4)

Non-GAAP Adjusted income and its components and Non-GAAP Adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, Non-GAAP Adjusted income and its components and Non-GAAP Adjusted diluted EPS are Non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, Non-GAAP Adjusted income and its components and Non-GAAP Adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP Adjusted income and its components and Non-GAAP Adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.


(5)	Exclusive of amortization of intangible assets, except as discussed in footnote (6) below.

- 20 -

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

CERTAIN LINE ITEMS

(UNAUDITED)

(6)

- 21 -

PFIZER INC.

REVENUES

FOURTH QUARTER 2013 AND 2012

(UNAUDITED)

(millions of dollars)



	WORLDWIDE						UNITED STATES					TOTAL INTERNATIONAL^(a)
	2013		2012		% Change		2013		2012		% Change	2013		2012		% Change
					Total	Oper.					Total					Total	Oper.
TOTAL REVENUES	$	13,558	$	13,891	(2%)	1%	$	5,084	$	5,301	(4%)	$	8,474	$	8,590	(1%)	3%
REVENUES FROM BIOPHARMACEUTICAL PRODUCTS:	$	12,480	$	12,893	(3%)	—	$	4,568	$	4,809	(5%)	$	7,912	$	8,084	(2%)	3%
Lyrica	1,260		1,132		11%	14%	525		443		19%	735		689		7%	11%
Prevnar family	1,119		1,089		3%	4%	468		464		1%	651		625		4%	7%
Enbrel (Outside the U.S. and Canada)	1,005		957		5%	8%	—		—		—	1,005		957		5%	8%
Celebrex	798		750		6%	9%	524		479		9%	274		271		1%	9%
Lipitor	611		584		5%	8%	97		61		59%	514		523		(2%)	3%
Viagra	476		553		(14%)	(13%)	313		313		—	163		240		(32%)	(30%)
Zyvox	346		349		(1%)	1%	177		175		1%	169		174		(3%)	1%
Norvasc	312		348		(10%)	(3%)	8		10		(20%)	304		338		(10%)	(3%)
Sutent	312		323		(3%)	(2%)	90		82		10%	222		241		(8%)	(6%)
Premarin family	299		276		8%	9%	275		253		9%	24		23		4%	9%
BeneFIX	213		198		8%	8%	97		86		13%	116		112		4%	5%
Vfend	218		211		3%	7%	12		25		(52%)	206		186		11%	14%
Genotropin	202		213		(5%)	—	54		54		—	148		159		(7%)	—
Pristiq	182		169		8%	10%	138		128		8%	44		41		7%	15%
Chantix/Champix	162		174		(7%)	(4%)	90		79		14%	72		95		(24%)	(18%)
Refacto AF/Xyntha	169		164		3%	2%	34		27		26%	135		137		(1%)	(3%)
Xalatan/Xalacom	155		189		(18%)	(12%)	7		8		(13%)	148		181		(18%)	(12%)
Detrol/Detrol LA	125		185		(32%)	(31%)	78		124		(37%)	47		61		(23%)	(19%)
Zoloft	128		143		(10%)	—	14		19		(26%)	114		124		(8%)	4%
Medrol	121		135		(10%)	(8%)	38		35		9%	83		100		(17%)	(13%)
Effexor	114		83		37%	40%	45		7		*	69		76		(9%)	(7%)
Zosyn/Tazocin	102		106		(4%)	(3%)	45		42		7%	57		64		(11%)	(10%)
Zithromax/Zmax	104		117		(11%)	(3%)	2		3		(33%)	102		114		(11%)	(2%)
Fragmin	96		98		(2%)	(2%)	2		6		(67%)	94		92		2%	4%
Relpax	96		102		(6%)	(4%)	57		59		(3%)	39		43		(9%)	(5%)
Tygacil	87		86		1%	3%	28		37		(24%)	59		49		20%	23%
Rapamune	89		87		2%	4%	49		45		9%	40		42		(5%)	1%
Inlyta	102		47		117%	126%	43		30		43%	59		17		*	*
Sulperazon	87		71		23%	24%	—		—		—	87		71		23%	24%
Revatio	82		120		(32%)	(30%)	15		62		(76%)	67		58		16%	20%
Cardura	75		84		(11%)	(4%)	1		1		—	74		83		(11%)	(4%)
Xalkori	89		45		98%	105%	41		24		71%	48		21		129%	147%
Xanax XR	72		71		1%	2%	13		12		8%	59		59		—	2%
Diflucan	78		74		5%	7%	1		—		*	77		74		4%	6%
Toviaz	62		57		9%	9%	31		31		—	31		26		19%	18%
Aricept^(b)	62		77		(19%)	(16%)	—		—		—	62		77		(19%)	(16%)
Inspra	69		58		19%	22%	2		1		100%	67		57		18%	22%
Caduet	59		67		(12%)	(3%)	7		7		—	52		60		(13%)	(2%)
Somavert	58		55		5%	6%	14		13		8%	44		42		5%	6%
Neurontin	58		63		(8%)	(4%)	12		11		9%	46		52		(12%)	(5%)
Unasyn	54		63		(14%)	—	—		—		—	54		63		(14%)	—
BMP2	51		71		(28%)	(28%)	51		71		(28%)	—		—		—	—
Geodon	77		31		148%	149%	50		—		*	27		31		(13%)	(21%)
Depo-Provera	52		45		16%	18%	11		11		—	41		34		21%	24%
Aromasin	50		48		4%	7%	3		3		—	47		45		4%	9%
Xeljanz	46		6		*	*	45		6		*	1		—		*	*
Alliance revenues^(c)	441		915		(52%)	(51%)	366		712		(49%)	75		203		(63%)	(61%)
All other biopharmaceutical products^(d)	1,855		2,004		(7%)	(3%)	595		750		(21%)	1,260		1,254		—	8%
All other established products^(d)	1,561		1,565		—	4%	532		532		—	1,029		1,033		—	5%
REVENUES FROM OTHER PRODUCTS:
CONSUMER HEALTHCARE	$	943	$	936	1%	2%	$	469	$	472	(1%)	$	474	$	464	2%	5%
OTHER^(e)	$	135	$	62	*	*	$	47	$	20	*	$	88	$	42	*	*



*	Indicates calculation not meaningful.
(a)	Total International represents Developed Europe region + Developed Rest of World region + Emerging Markets region. Details for these regions are located on the following page.
(b)	Represents direct sales under license agreement with Eisai Co., Ltd.
(c)	Includes Enbrel (in the U.S. and Canada through October 31, 2013), Spiriva, Rebif, Aricept and Eliquis.
(d)	All other established products is a subset of All other biopharmaceutical products.
(e)	Other represents revenues generated from Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales organization, and includes, in 2013, the revenues related to our transitional manufacturing and supply agreements with Zoetis.
Certain amounts and percentages may reflect rounding adjustments.

- 22 -

PFIZER INC.

INTERNATIONAL REVENUES BY GEOGRAPHIC REGION

FOURTH QUARTER 2013 and 2012

(UNAUDITED)

(millions of dollars)



	DEVELOPED EUROPE^(a)						DEVELOPED REST OF WORLD^(b)						EMERGING MARKETS^(c)
	2013		2012		% Change		2013		2012		% Change		2013		2012		% Change
	2013		2012		Total	Oper.	2013		2012		Total	Oper.	2013		2012		Total	Oper.
TOTAL INTERNATIONAL REVENUES	$	3,237	$	3,128	3%	—	$	2,207	$	2,558	(14%)	1%	$	3,030	$	2,904	4%	9%
REVENUES FROM BIOPHARMACEUTICAL PRODUCTS - INTERNATIONAL:	$	3,073	$	2,984	3%	(1%)	$	2,090	$	2,448	(15%)	—	$	2,749	$	2,652	4%	9%
Lyrica	413		364		13%	9%	183		217		(16%)	2%	139		108		29%	37%
Prevnar family	251		208		21%	16%	151		153		(1%)	11%	249		264		(6%)	(2%)
Enbrel (Outside Canada)	659		627		5%	2%	137		104		32%	56%	209		226		(8%)	3%
Celebrex	41		40		3%	(2%)	130		138		(6%)	8%	103		93		11%	14%
Lipitor	92		107		(14%)	(18%)	129		201		(36%)	(25%)	293		215		36%	39%
Viagra	37		103		(64%)	(65%)	39		49		(20%)	(14%)	87		88		(1%)	1%
Zyvox	87		78		12%	7%	35		39		(10%)	8%	47		57		(18%)	(12%)
Norvasc	28		28		—	(5%)	121		171		(29%)	(15%)	155		139		12%	13%
Sutent	109		114		(4%)	(8%)	37		48		(23%)	(9%)	76		79		(4%)	—
Premarin family	2		3		(33%)	(2%)	11		9		22%	13%	11		11		—	7%
BeneFIX	71		66		8%	4%	38		39		(3%)	7%	7		7		—	18%
Vfend	83		78		6%	2%	44		44		—	16%	79		64		23%	28%
Genotropin	71		71		—	(3%)	50		58		(14%)	6%	27		30		(10%)	(5%)
Pristiq	1		—		*	*	31		28		11%	21%	12		13		(8%)	(7%)
Chantix/Champix	28		35		(20%)	(24%)	34		47		(28%)	(16%)	10		13		(23%)	(12%)
Refacto AF/Xyntha	108		99		9%	6%	18		20		(10%)	(1%)	9		18		(50%)	(50%)
Xalatan/Xalacom	44		55		(20%)	(23%)	60		79		(24%)	(7%)	44		47		(6%)	(6%)
Detrol/Detrol LA	12		22		(45%)	(50%)	23		28		(18%)	(7%)	12		11		9%	10%
Zoloft	16		15		7%	5%	58		71		(18%)	1%	40		38		5%	9%
Medrol	23		24		(4%)	(5%)	10		12		(17%)	(5%)	50		64		(22%)	(18%)
Effexor	26		26		—	(2%)	17		22		(23%)	(16%)	26		28		(7%)	(3%)
Zosyn/Tazocin	10		11		(9%)	(14%)	2		2		—	18%	45		51		(12%)	(10%)
Zithromax/Zmax	15		14		7%	8%	35		52		(33%)	(16%)	52		48		8%	11%
Fragmin	53		47		13%	9%	24		26		(8%)	8%	17		19		(11%)	(14%)
Relpax	19		20		(5%)	(9%)	14		17		(18%)	(1%)	6		6		—	(2%)
Tygacil	19		17		12%	7%	2		2		—	(14%)	38		30		27%	35%
Rapamune	14		15		(7%)	(8%)	4		5		(20%)	4%	22		22		—	6%
Inlyta	31		3		*	*	25		13		92%	123%	3		1		*	*
Sulperazon	—		—		—	—	8		9		(11%)	(5%)	79		62		27%	28%
Revatio	45		33		36%	33%	15		16		(6%)	16%	7		9		(22%)	(20%)
Cardura	22		25		(12%)	(17%)	24		32		(25%)	(6%)	28		26		8%	12%
Xalkori	24		8		*	*	12		8		50%	75%	12		5		140%	155%
Xanax XR	28		24		17%	12%	9		11		(18%)	(6%)	22		24		(8%)	(5%)
Diflucan	15		13		15%	5%	9		11		(18%)	—	53		50		6%	8%
Toviaz	24		22		9%	6%	4		1		*	*	3		3		—	18%
Aricept^(d)	9		17		(47%)	(49%)	44		51		(14%)	(9%)	9		9		—	5%
Inspra	46		35		31%	28%	16		17		(6%)	14%	5		5		—	9%
Caduet	5		4		25%	3%	36		41		(12%)	5%	11		15		(27%)	(22%)
Somavert	36		34		6%	2%	4		5		(20%)	5%	4		3		33%	48%
Neurontin	16		13		23%	15%	9		14		(36%)	(17%)	21		25		(16%)	(10%)
Unasyn	11		12		(8%)	(18%)	17		21		(19%)	4%	26		30		(13%)	3%
BMP2	—		—		—	—	—		—		—	—	—		—		—	—
Geodon	8		13		(38%)	(46%)	5		5		—	13%	14		13		8%	2%
Depo-Provera	7		8		(13%)	—	4		3		33%	—	30		23		30%	36%
Aromasin	15		16		(6%)	(12%)	8		13		(38%)	(20%)	24		16		50%	55%
Xeljanz	—		—		—	—	—		—		—	—	1		—		*	*
Alliance revenues^(e)	29		38		(24%)	(28%)	37		151		(75%)	(71%)	9		14		(36%)	(35%)
All other biopharmaceutical products^(f)	370		379		(2%)	(6%)	367		345		6%	25%	523		530		(1%)	6%
All other established products^(f)	289		281		3%	(1%)	284		265		7%	25%	456		487		(6%)	(2%)
REVENUES FROM OTHER PRODUCTS - INTERNATIONAL	$	164	$	144	14%	11%	$	117	$	110	6%	12%	$	281	$	252	12%	15%



*	Indicates calculation not meaningful.
(a)	Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries.
(b)	Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand and South Korea.
(c)	Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe.
(d)	Represents direct sales under license agreement with Eisai Co., Ltd.
(e)	Includes Enbrel (in Canada through October 31, 2013), Spiriva, Aricept and Eliquis.
(f)	All other established products is a subset of All other biopharmaceutical products.
Certain amounts and percentages may reflect rounding adjustments.

- 23 -

PFIZER INC.

REVENUES

TWELVE MONTHS 2013 and 2012

(UNAUDITED)

(millions of dollars)



	WORLDWIDE						UNITED STATES					TOTAL INTERNATIONAL^(a)
	2013		2012		% Change		2013		2012		% Change	2013		2012		% Change
					Total	Oper.					Total					Total	Oper.
TOTAL REVENUES	$	51,584	$	54,657	(6%)	(4%)	$	20,274	$	21,313	(5%)	$	31,310	$	33,344	(6%)	(3%)
REVENUES FROM BIOPHARMACEUTICAL PRODUCTS:	$	47,878	$	51,214	(7%)	(4%)	$	18,570	$	19,708	(6%)	$	29,308	$	31,506	(7%)	(3%)
Lyrica	4,595		4,158		11%	13%	1,963		1,672		17%	2,632		2,486		6%	10%
Prevnar family	3,974		4,117		(3%)	(2%)	1,804		1,887		(4%)	2,170		2,230		(3%)	—
Enbrel (Outside the U.S. and Canada)	3,774		3,737		1%	4%	—		—		—	3,774		3,737		1%	4%
Celebrex	2,918		2,719		7%	9%	1,933		1,745		11%	985		974		1%	7%
Lipitor	2,315		3,948		(41%)	(40%)	432		932		(54%)	1,883		3,016		(38%)	(35%)
Viagra	1,881		2,051		(8%)	(8%)	1,132		1,135		—	749		916		(18%)	(17%)
Zyvox	1,353		1,345		1%	3%	688		665		3%	665		680		(2%)	2%
Norvasc	1,229		1,349		(9%)	(3%)	39		48		(19%)	1,190		1,301		(9%)	(2%)
Sutent	1,204		1,236		(3%)	(1%)	351		337		4%	853		899		(5%)	(3%)
Premarin family	1,092		1,073		2%	2%	1,001		977		2%	91		96		(5%)	(1%)
BeneFIX	832		775		7%	8%	395		358		10%	437		417		5%	7%
Vfend	775		754		3%	6%	61		89		(31%)	714		665		7%	11%
Genotropin	772		832		(7%)	(3%)	199		204		(2%)	573		628		(9%)	(3%)
Pristiq	698		630		11%	12%	540		493		10%	158		137		15%	20%
Chantix/Champix	648		670		(3%)	(1%)	343		313		10%	305		357		(15%)	(10%)
Refacto AF/Xyntha	602		584		3%	2%	123		106		16%	479		478		—	(1%)
Xalatan/Xalacom	589		806		(27%)	(22%)	30		38		(21%)	559		768		(27%)	(22%)
Detrol/Detrol LA	562		761		(26%)	(25%)	375		486		(23%)	187		275		(32%)	(29%)
Zoloft	469		541		(13%)	(5%)	44		68		(35%)	425		473		(10%)	—
Medrol	464		523		(11%)	(9%)	148		140		6%	316		383		(17%)	(15%)
Effexor	440		425		4%	4%	173		109		59%	267		316		(16%)	(15%)
Zosyn/Tazocin	395		484		(18%)	(18%)	172		217		(21%)	223		267		(16%)	(16%)
Zithromax/Zmax	387		435		(11%)	(5%)	7		12		(42%)	380		423		(10%)	(4%)
Fragmin	359		381		(6%)	(6%)	23		42		(45%)	336		339		(1%)	(1%)
Relpax	359		368		(2%)	(1%)	218		219		—	141		149		(5%)	(2%)
Tygacil	358		335		7%	8%	150		152		(1%)	208		183		14%	16%
Rapamune	350		346		1%	2%	201		185		9%	149		161		(7%)	(4%)
Inlyta	319		100		*	*	155		82		89%	164		18		*	*
Sulperazon	309		262		18%	19%	—		—		—	309		262		18%	19%
Revatio	307		534		(43%)	(41%)	67		312		(79%)	240		222		8%	11%
Cardura	296		338		(12%)	(7%)	4		5		(20%)	292		333		(12%)	(7%)
Xalkori	282		123		129%	134%	139		80		74%	143		43		*	*
Xanax	276		274		1%	2%	49		50		(2%)	227		224		1%	3%
Diflucan	242		259		(7%)	(4%)	3		4		(25%)	239		255		(6%)	(4%)
Toviaz	236		207		14%	14%	120		113		6%	116		94		23%	24%
Aricept^(b)	235		326		(28%)	(27%)	—		—		—	235		326		(28%)	(27%)
Inspra	233		214		9%	13%	6		5		20%	227		209		9%	13%
Caduet	223		258		(14%)	(7%)	23		33		(30%)	200		225		(11%)	(4%)
Somavert	217		197		10%	10%	52		46		13%	165		151		9%	9%
Neurontin	216		235		(8%)	(5%)	45		48		(6%)	171		187		(9%)	(5%)
Unasyn	212		228		(7%)	5%	1		2		(50%)	211		226		(7%)	5%
BMP2	209		263		(21%)	(21%)	209		263		(21%)	—		—		—	—
Geodon	194		353		(45%)	(45%)	84		214		(61%)	110		139		(21%)	(20%)
Depo-Provera	191		148		29%	31%	57		33		73%	134		115		17%	19%
Aromasin	185		210		(12%)	(9%)	12		14		(14%)	173		196		(12%)	(10%)
Xeljanz	114		6		*	*	112		6		*	2		—		*	*
Alliance revenues^(c)	2,628		3,492		(25%)	(24%)	2,267		2,620		(13%)	361		872		(59%)	(57%)
All other biopharmaceutical products^(d)	7,360		7,804		(6%)	(2%)	2,620		3,149		(17%)	4,740		4,655		2%	8%
All other established products^(d)	5,966		6,074		(2%)	1%	2,038		2,165		(6%)	3,928		3,909		1%	5%
REVENUES FROM OTHER PRODUCTS:
CONSUMER HEALTHCARE	$	3,342	$	3,212	4%	5%	$	1,580	$	1,526	4%	$	1,762	$	1,686	5%	6%
OTHER^(e)	$	364	$	231	58%	57%	$	124	$	79	57%	$	240	$	152	58%	57%



*	Indicates calculation not meaningful.
(a)	Total International represents Developed Europe region + Developed Rest of World region + Emerging Markets region. Details for these regions are located on the following page.
(b)	Represents direct sales under license agreement with Eisai Co., Ltd.
(c)	Includes Enbrel (in the U.S. and Canada through October 31, 2013), Spiriva, Rebif, Aricept and Eliquis.
(d)	All other established products is a subset of All other biopharmaceutical products.
(e)	Other represents revenues generated from Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales organization, and includes, in 2013, the revenues related to our transitional manufacturing and supply agreements with Zoetis.
Certain amounts and percentages may reflect rounding adjustments.

- 24 -

PFIZER INC.

INTERNATIONAL REVENUES BY GEOGRAPHIC REGION

TWELVE MONTHS 2013 and 2012

(UNAUDITED)

(millions of dollars)



	DEVELOPED EUROPE^(a)						DEVELOPED REST OF WORLD^(b)						EMERGING MARKETS^(c)
	2013		2012		% Change		2013		2012		% Change		2013		2012		% Change
	2013		2012		Total	Oper.	2013		2012		Total	Oper.	2013		2012		Total	Oper.
TOTAL INTERNATIONAL REVENUES	$	11,739	$	12,545	(6%)	(8%)	$	8,346	$	9,956	(16%)	(5%)	$	11,225	$	10,843	4%	7%
REVENUES FROM BIOPHARMACEUTICAL PRODUCTS - INTERNATIONAL:	$	11,156	$	12,010	(7%)	(9%)	$	7,937	$	9,536	(17%)	(6%)	$	10,215	$	9,960	3%	6%
Lyrica	1,458		1,319		11%	8%	680		743		(8%)	6%	494		424		17%	20%
Prevnar family	758		704		8%	5%	536		612		(12%)	(2%)	876		914		(4%)	(2%)
Enbrel (Outside Canada)	2,413		2,318		4%	2%	516		555		(7%)	7%	845		864		(2%)	6%
Celebrex	151		161		(6%)	(9%)	464		479		(3%)	8%	370		334		11%	12%
Lipitor	319		1,149		(72%)	(73%)	510		978		(48%)	(41%)	1,054		889		19%	20%
Viagra	265		370		(28%)	(29%)	152		201		(24%)	(19%)	332		345		(4%)	(3%)
Zyvox	325		302		8%	5%	136		154		(12%)	3%	204		224		(9%)	(3%)
Norvasc	108		119		(9%)	(12%)	485		659		(26%)	(14%)	597		523		14%	14%
Sutent	402		439		(8%)	(11%)	140		176		(20%)	(11%)	311		284		10%	13%
Premarin family	9		10		(10%)	(5%)	37		36		3%	4%	45		50		(10%)	(4%)
BeneFIX	257		248		4%	1%	139		137		1%	10%	41		32		28%	33%
Vfend	305		281		9%	6%	154		162		(5%)	10%	255		222		15%	17%
Genotropin	268		295		(9%)	(11%)	197		224		(12%)	4%	108		109		(1%)	5%
Pristiq	1		—		*	*	105		90		17%	21%	52		47		11%	16%
Chantix/Champix	116		129		(10%)	(11%)	143		179		(20%)	(13%)	46		49		(6%)	—
Refacto AF/Xyntha	386		373		3%	1%	70		64		9%	15%	23		41		(44%)	(42%)
Xalatan/Xalacom	161		275		(41%)	(43%)	232		311		(25%)	(13%)	166		182		(9%)	(7%)
Detrol/Detrol LA	53		119		(55%)	(56%)	86		102		(16%)	(7%)	48		54		(11%)	(9%)
Zoloft	63		59		7%	5%	221		278		(21%)	(5%)	141		136		4%	7%
Medrol	90		94		(4%)	(6%)	39		48		(19%)	(7%)	187		241		(22%)	(20%)
Effexor	96		110		(13%)	(14%)	68		102		(33%)	(32%)	103		104		(1%)	3%
Zosyn/Tazocin	40		48		(17%)	(19%)	12		13		(8%)	(10%)	171		206		(17%)	(15%)
Zithromax/Zmax	59		59		—	(2%)	130		186		(30%)	(17%)	191		178		7%	9%
Fragmin	183		182		1%	(1%)	89		84		6%	10%	64		73		(12%)	(13%)
Relpax	69		70		(1%)	(4%)	52		60		(13%)	(2%)	20		19		5%	7%
Tygacil	72		67		7%	5%	7		7		—	7%	129		109		18%	23%
Rapamune	52		54		(4%)	(6%)	17		18		(6%)	3%	80		89		(10%)	(5%)
Inlyta	77		4		*	*	81		13		*	*	6		1		*	*
Sulperazon	—		—		—	—	28		36		(22%)	(8%)	281		226		24%	23%
Revatio	157		133		18%	16%	52		56		(7%)	10%	31		33		(6%)	(5%)
Cardura	86		97		(11%)	(13%)	100		134		(25%)	(11%)	106		102		4%	6%
Xalkori	65		19		*	*	45		17		165%	*	33		7		*	*
Xanax	101		89		13%	10%	35		44		(20%)	(9%)	91		91		—	1%
Diflucan	52		60		(13%)	(16%)	33		41		(20%)	(6%)	154		154		—	1%
Toviaz	85		76		12%	9%	19		8		138%	142%	12		10		20%	30%
Aricept^(d)	43		110		(61%)	(62%)	160		177		(10%)	(8%)	32		39		(18%)	(15%)
Inspra	150		131		15%	12%	58		61		(5%)	13%	19		17		12%	20%
Caduet	14		14		—	(7%)	142		149		(5%)	6%	44		62		(29%)	(27%)
Somavert	134		123		9%	6%	16		17		(6%)	11%	15		11		36%	37%
Neurontin	53		58		(9%)	(10%)	37		45		(18%)	(9%)	81		84		(4%)	1%
Unasyn	40		39		3%	(1%)	68		76		(11%)	8%	103		111		(7%)	5%
BMP2	—		—		—	—	—		—		—	—	—		—		—	—
Geodon	43		61		(30%)	(32%)	19		21		(10%)	(8%)	48		57		(16%)	(11%)
Depo-Provera	27		27		—	3%	13		13		—	(2%)	94		75		25%	28%
Aromasin	57		73		(22%)	(24%)	36		54		(33%)	(21%)	80		69		16%	15%
Xeljanz	—		—		—	—	1		—		*	*	1		—		*	*
Alliance revenues^(e)	118		242		(51%)	(53%)	201		565		(64%)	(61%)	42		65		(35%)	(34%)
All other biopharmaceutical products^(f)	1,375		1,300		6%	3%	1,376		1,351		2%	17%	1,989		2,004		(1%)	4%
All other established products^(f)	1,083		1,050		3%	1%	1,063		1,051		1%	15%	1,782		1,808		(1%)	1%
REVENUES FROM OTHER PRODUCTS - INTERNATIONAL	$	583	$	535	9%	7%	$	409	$	420	(3%)	—	$	1,010	$	883	14%	17%



*	Indicates calculation not meaningful.
(a)	Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries.
(b)	Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand and South Korea.
(c)	Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe.
(d)	Represents direct sales under license agreement with Eisai Co., Ltd.
(e)	Includes Enbrel (in Canada through October 31, 2013), Spiriva, Aricept and Eliquis.
(f)	All other established products is a subset of All other biopharmaceutical products.
Certain amounts and percentages may reflect rounding adjustments.

- 25 -

DISCLOSURE NOTICE: The information contained in this earnings release and the attachments is as of January 28, 2014. We assume no obligation to update forward-looking statements contained in this earnings release and the attachments as a result of new information or future events or developments.

This earnings release and the attachments contain forward-looking statements about our future operating and financial performance, business plans and prospects, in-line products and product candidates, strategic reviews, capital allocation, business-development plans, and plans relating to share repurchases and dividends, among other things, that involve substantial risks and uncertainties. You can identify these statements by the fact that they use future dates or use words such as “will,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” “forecast,” “goal,” “objective,” “aim” and other words and terms of similar meaning. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following:

▪

the outcome of research and development activities, including, without limitation, the ability to meet anticipated clinical trial commencement and completion dates, regulatory submission and approval dates, and launch dates for product candidates, as well as the possibility of unfavorable clinical trial results, including unfavorable new clinical data and additional analyses of existing clinical data;


▪	decisions by regulatory authorities regarding whether and when to approve our drug applications, as well as their decisions regarding labeling, ingredients and other matters that could affect the availability or commercial potential of our products;


▪	the speed with which regulatory authorizations, pricing approvals and product launches may be achieved;


▪	the outcome of post-approval clinical trials, which could result in the loss of marketing approval for a product or changes in the labeling for, and/or increased or new concerns about the safety or efficacy of, a product that could affect its availability or commercial potential;


▪	the success of external business-development activities;


▪	competitive developments, including the impact on our competitive position of new product entrants, in-line branded products, generic products, private label products and product candidates that treat diseases and conditions similar to those treated by our in-line drugs and drug candidates;


▪	the implementation by the FDA of an abbreviated legal pathway to approve biosimilar products, which could subject our biologic products to competition from biosimilar products in the U.S., with attendant competitive pressures, after the expiration of any applicable exclusivity period and patent rights;


▪	the ability to meet generic and branded competition after the loss of patent protection for our products or competitor products;


▪	the ability to successfully market both new and existing products domestically and internationally;


▪	difficulties or delays in manufacturing;


▪	trade buying patterns;


▪	the impact of existing and future legislation and regulatory provisions on product exclusivity;


▪	trends toward managed care and healthcare cost containment;


▪	the impact of the U.S. Budget Control Act of 2011 (the Budget Control Act) and the deficit-reduction actions to be taken pursuant to the Budget Control Act in order to achieve the deficit-reduction targets provided for therein, and the impact of any broader deficit-reduction efforts;

▪

the inability of the U.S. federal government to conduct drug review and approval activities or to satisfy its financial obligations, including under Medicare, Medicaid and other publicly funded or subsidized health programs, that may result from the possible failure of the U.S. federal government in the future to provide funding to avoid a partial or total shutdown of its operations and/or to suspend enforcement of or to increase the federal debt ceiling;


▪	the impact of U.S. healthcare legislation enacted in 2010—the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act—and of any modification or repeal of any of the provisions thereof;


▪	U.S. federal or state legislation or regulatory action affecting, among other things: pharmaceutical product pricing, reimbursement or access, including under Medicaid, Medicare and other publicly funded or subsidized health

- 26 -

programs; the importation of prescription drugs from outside the U.S. at prices that are regulated by governments of various foreign countries; direct-to-consumer advertising and interactions with healthcare professionals; and the use of comparative effectiveness methodologies that could be implemented in a manner that focuses primarily on the cost differences and minimizes the therapeutic differences among pharmaceutical products and restricts access to innovative medicines;


▪	legislation or regulatory action in markets outside the U.S. affecting pharmaceutical product pricing, reimbursement or access, including, in particular, continued government-mandated price reductions for certain biopharmaceutical products in certain European and emerging market countries;


▪	the exposure of our operations outside the U.S. to possible capital and exchange controls, expropriation and other restrictive government actions, changes in intellectual property legal protections and remedies, as well as political unrest and unstable governments and legal systems;


▪	contingencies related to actual or alleged environmental contamination;


▪	claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates;


▪	any significant breakdown, infiltration, or interruption of our information technology systems and infrastructure;


▪	legal defense costs, insurance expenses, settlement costs, the risk of an adverse decision or settlement and the adequacy of reserves related to product liability, patent protection, government investigations, consumer, commercial, securities, antitrust, environmental and tax issues, ongoing efforts to explore various means for resolving asbestos litigation, and other legal proceedings;


▪	our ability to protect our patents and other intellectual property, both domestically and internationally;


▪	interest rate and foreign currency exchange rate fluctuations, including the impact of possible currency devaluations in countries experiencing high inflation rates;


▪	governmental laws and regulations affecting domestic and foreign operations, including, without limitation, tax obligations and changes affecting the tax treatment by the U.S. of income earned outside of the U.S. that may result from pending and possible future proposals;


▪	any significant issues involving our largest wholesaler customers, which account for a substantial portion of our revenues;


▪	the possible impact of the increased presence of counterfeit medicines in the pharmaceutical supply chain on our revenues and on patient confidence in the integrity of our medicines;


▪	any significant issues that may arise related to the outsourcing of certain operational and staff functions to third parties, including with regard to quality, timeliness and compliance with applicable legal requirements and industry standards;


▪	changes in U.S. generally accepted accounting principles;

▪

uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact on us, our customers, suppliers and lenders and counterparties to our foreign-exchange and interest-rate agreements of challenging global economic conditions and recent and possible future changes in global financial markets; and the related risk that our allowance for doubtful accounts may not be adequate;


▪	any changes in business, political and economic conditions due to actual or threatened terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas;


▪	growth in costs and expenses;


▪	changes in our product, segment and geographic mix; and

▪

the impact of acquisitions, divestitures, restructurings, internal reorganizations, product recalls and withdrawals and other unusual items, including our ability to realize the projected benefits of our cost-reduction and productivity initiatives, including those related to our research and development organization, and of the internal separation of our commercial operations into three, new, global businesses effective January 1, 2014.

A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K/A for the fiscal year ended December 31, 2012 and in our reports on Form 10-Q, in each case including in the sections thereof

- 27 -

captioned “Forward-Looking Information and Factors That May Affect Future Results” and “Item 1A. Risk Factors”, and in our reports on Form 8-K.

This earnings release may include discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data.

- 28 -

Attached files

Stock widget

Investing forum

PFIZER INC Reports